An Alzheimer’s drug significantly slowed Alzheimer’s disease in a new study, bolstering the drug’s prospects ahead of an FDA approval decision next year
their experimental Alzheimer’s disease drug
significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects for approval. The pharmaceutical companies said their drug lecanemab reduced cognitive and functional decline by 27%, compared with a placebo, over 18 months in a Phase 3 study of 1,800 patients with early-stage Alzheimer’s. The drug was also linked to higher rates of brain swelling and small bleeds, though the company said they were rarely symptomatic.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Biogen to pay $900M to settle allegations of improper physician kickbacksBiogen is accused of causing submissions of false claims to Medicare and Medicaid by paying physicians kickbacks to prescribe its multiple sclerosis drugs Avonex, Tysabri and Tecfidera.
Baca lebih lajut »
Biogen Agrees to Pay $900 Million Over Alleged Improper Physician PaymentsBiogen Inc. agreed to pay $900 million to settle allegations that it paid kickbacks to doctors to induce them to prescribe the company’s drugs, the Justice Department said
Baca lebih lajut »
Newly Discovered Protein Connected to Significant Increase in Risk of Alzheimer’s DiseaseA mutation in the small protein SHMOOSE is linked with increased Alzheimer’s risk and highlights a possible target for treatment. A mutation in a newly discovered small protein is associated with a substantial increase in the risk for Alzheimer’s disease, according to a new University of Southe
Baca lebih lajut »
Fundraiser held to help 3-year-old Austin Rose with rare neurological diseaseA.J.'s family needs help to make his home accessible, to pay for nursing care and to travel to Ohio for clinical drug trials.
Baca lebih lajut »
Time to Stop Approving Drugs From Single-Arm Trials?Many drugs approved over the last decade based solely on data from single-arm trials have been subsequently withdrawn when put through the rigors of a head-to-head RCT. ESMO22 OncTwitter MedTwitter
Baca lebih lajut »
Pa. woman charged with harassment, sending thousands of pornographic textsThe victims report that the texts have not slowed since her arrests.
Baca lebih lajut »